Register for the 7th Genome Editing Therapeutics Summit 2026
Please select the appropriate price when booking. Bookings are subject to approval.
All prices are shown in USD.
Limited FREE* Passes for Eligible Biopharma, Academics & Not-for-Profits
Drug Developer, Academic or Not-for-Profit Pricing
Conference Only
FREE*
T&C's Apply
Service or Solution Provider Pricing**
Conference Only
(Register by Monday, September 28 & Save $100)
$3,799
On the Door: $3,899
*Free passes are available to drug developers, research organizations, academic institutions and not-for-profits only. Please note that credit card details will be taken upon registration, and a nominal fee of $0.50 charged. Free access is only granted once approval of eligibility is confirmed. Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and paid registration will then be required to access the event. Hanson Wade reserves the right to charge free access guests a non-refundable charge of $100 if they do not attend the entire event if they fail to give 7 working days’ notice of non-attendance.
** If you are a solution or service provider, have you considered sponsoring this event? Sponsorship includes multiple passes at a discounted rate. Inquire to learn more.
Unlock Group Discounts
Maximize value for money using special team discounts: Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.
10% Off
When registering 2 attendees from one company
15% Off
When registering 3 attendees from one company
20% Off
When registering 4+ attendees from one company
Need Assistance?
If you have any questions about registration pricing, discounts or would like help in the booking process, contact us and one of the team will get back to you.
Explore the Full Event Guide
- 2 days of content to find the sessions your program needs most
- 50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage
- 80% Directors, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers
- 64% in vivo & 36% ex vivo agenda to fit your route of delivery
- See how Intellia, Beam Therapeutics & others closest to approval are contributing to the meeting
